CN101675074B - 抗体及其制备和使用方法 - Google Patents

抗体及其制备和使用方法 Download PDF

Info

Publication number
CN101675074B
CN101675074B CN200780051557.6A CN200780051557A CN101675074B CN 101675074 B CN101675074 B CN 101675074B CN 200780051557 A CN200780051557 A CN 200780051557A CN 101675074 B CN101675074 B CN 101675074B
Authority
CN
China
Prior art keywords
seq
amino acid
antibody
variable region
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200780051557.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN101675074A (zh
Inventor
G·弗赖
B·E·基梅尔
A·安德松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MMR INFORMATION SYSTEMS Inc
MMRGlobal Inc
Original Assignee
MMR INFORMATION SYSTEMS Inc
MMRGlobal Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MMR INFORMATION SYSTEMS Inc, MMRGlobal Inc filed Critical MMR INFORMATION SYSTEMS Inc
Priority to CN201310355119.6A priority Critical patent/CN103709249B/zh
Publication of CN101675074A publication Critical patent/CN101675074A/zh
Application granted granted Critical
Publication of CN101675074B publication Critical patent/CN101675074B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
CN200780051557.6A 2006-12-20 2007-09-14 抗体及其制备和使用方法 Expired - Fee Related CN101675074B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310355119.6A CN103709249B (zh) 2006-12-20 2007-09-14 抗体及其制备和使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87106906P 2006-12-20 2006-12-20
US60/871,069 2006-12-20
PCT/US2007/078568 WO2008079466A1 (en) 2006-12-20 2007-09-14 Antibodies and methods for making and using them

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201310355119.6A Division CN103709249B (zh) 2006-12-20 2007-09-14 抗体及其制备和使用方法

Publications (2)

Publication Number Publication Date
CN101675074A CN101675074A (zh) 2010-03-17
CN101675074B true CN101675074B (zh) 2016-02-24

Family

ID=39536929

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200780051557.6A Expired - Fee Related CN101675074B (zh) 2006-12-20 2007-09-14 抗体及其制备和使用方法
CN201310355119.6A Expired - Fee Related CN103709249B (zh) 2006-12-20 2007-09-14 抗体及其制备和使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201310355119.6A Expired - Fee Related CN103709249B (zh) 2006-12-20 2007-09-14 抗体及其制备和使用方法

Country Status (10)

Country Link
US (3) US8465741B2 (https=)
EP (3) EP2716657A3 (https=)
JP (3) JP2010513539A (https=)
KR (2) KR101546441B1 (https=)
CN (2) CN101675074B (https=)
AU (1) AU2007338607B2 (https=)
BR (1) BRPI0720565A2 (https=)
CA (2) CA2832111A1 (https=)
MX (1) MX2009006659A (https=)
WO (2) WO2008079466A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0720565A2 (pt) * 2006-12-20 2013-09-17 Mmr Information Systems Inc anticorpos e mÉtodos para a sua preparaÇço e seu uso
EP3181583A1 (en) 2009-02-24 2017-06-21 ESBATech, an Alcon Biomedical Research Unit LLC Methods for identifying immunobinders of antigens
CN103037900B (zh) 2010-02-24 2016-04-06 伊缪诺金公司 叶酸受体1抗体与免疫缀合物以及其用途
JP2013529076A (ja) 2010-05-11 2013-07-18 アベオ ファーマシューティカルズ， インコーポレイテッド 抗ｆｇｆｒ２抗体
CN103620405B (zh) * 2010-12-31 2016-05-25 生物蛋白有限公司 全面单克隆抗体产生
US9683054B2 (en) * 2010-12-31 2017-06-20 BioAlta, LLC Express humanization of antibodies
EP2673635A4 (en) * 2011-02-07 2015-08-12 Neotope Biosciences Ltd IMMUNOTHERAPY THROUGH APOE
IL281714B2 (en) 2011-04-01 2023-11-01 Immunogen Inc Methods for increasing the effectiveness of FOLR1 cancer therapy
CA2853637C (en) 2011-10-26 2023-04-04 Novartis Ag Anti-canine cd20 monoclonal antibodies and methods of use
US12384848B2 (en) 2011-12-19 2025-08-12 The Rockefeller University Anti-inflammatory polypeptides
EP2793943B1 (en) 2011-12-19 2018-09-26 The Rockefeller University Non-sialylated anti-inflammatory polypeptides
HUE049693T2 (hu) 2012-08-31 2020-10-28 Immunogen Inc Diagnosztikai ASSAY-k és készletek a folát receptor 1 kimutatására
CN109776676A (zh) 2012-11-28 2019-05-21 Cnj控股公司 针对艰难梭菌的抗体
AU2014312086B2 (en) 2013-08-30 2020-03-12 Immunogen, Inc. Antibodies and assays for detection of folate receptor 1
AU2016226115B2 (en) 2015-03-04 2021-03-25 The Rockefeller University Anti-inflammatory polypeptides
AU2016323968B2 (en) 2015-09-17 2023-07-06 Immunogen, Inc. Therapeutic combinations comprising anti-FOLR1 immunoconjugates
CN109689684B (zh) * 2016-07-06 2022-09-23 细胞基因公司 具有低免疫原性的抗体及其用途
KR102733407B1 (ko) * 2017-08-03 2024-11-21 알렉터 엘엘씨 항-cd33 항체 및 이의 이용 방법
CA3109726A1 (en) * 2018-08-31 2020-03-05 Immune Biosolutions Inc Antibodies specific for ntsr1 and uses thereof
CN111662382A (zh) * 2019-03-06 2020-09-15 瑞阳(苏州)生物科技有限公司 特异结合cd3的抗体、抗原结合片段和单链抗体可变区片段及其应用
JP7370569B2 (ja) * 2019-08-07 2023-10-30 国立大学法人 大分大学 アミロイドβタンパク質オリゴマーと結合するヒト化抗体
CN115803340A (zh) * 2020-04-24 2023-03-14 纪念斯隆凯特琳癌症中心 抗cd3抗体及其用途
CN116635948A (zh) * 2020-12-07 2023-08-22 Absci公司 用于产生疾病相关蛋白质组合物的系统和方法
WO2025024323A1 (en) * 2023-07-21 2025-01-30 Bighat Biosciences, Inc. P- and e-selectin-binding compositions and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003068821A2 (en) * 2002-02-14 2003-08-21 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
WO2004106380A2 (en) * 2003-05-31 2004-12-09 Micromet Ag Human-anti-human cd3 binding molecules
CN1867586A (zh) * 2003-10-16 2006-11-22 麦克罗梅特股份公司 多特异性的去免疫化cd3结合物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1400536A1 (en) * 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
DE69230545T2 (de) * 1991-08-21 2000-07-06 Novartis Ag, Basel Antikörperderivate
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US6764835B2 (en) 1995-12-07 2004-07-20 Diversa Corporation Saturation mutageneis in directed evolution
US6171820B1 (en) 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US6562594B1 (en) 1999-09-29 2003-05-13 Diversa Corporation Saturation mutagenesis in directed evolution
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
JP2000169393A (ja) * 1998-09-30 2000-06-20 Sankyo Co Ltd 抗Ｆａｓ抗体を含有する医薬
EP3029062A1 (en) 2000-05-26 2016-06-08 Bristol-Myers Squibb Company Soluble ctla4 mutant molecules and uses thereof
US20030026806A1 (en) * 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
US7321026B2 (en) * 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
AR044388A1 (es) * 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
US20060228350A1 (en) 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
ES2672640T3 (es) 2003-11-05 2018-06-15 Roche Glycart Ag Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
BRPI0508762A (pt) * 2004-04-16 2007-08-14 Genentech Inc método de aumento do esgotamento de células b em mamìferos, método de aumento da eficácia do esgotamento de células b, método de tratamento de malignidade ou neoplasma de células b, método de alìvio de disfunção autoimunológica regulada por células b, método de esgotamento das células b e composição
JP2007536246A (ja) 2004-05-05 2007-12-13 ジェネンテック・インコーポレーテッド 自己免疫疾患の予防法
PL1776384T3 (pl) * 2004-08-04 2013-10-31 Mentrik Biotech Llc WARIANTY REGIONÓW Fc
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP5153613B2 (ja) * 2005-03-18 2013-02-27 メディミューン，エルエルシー 抗体のフレームワーク・シャッフル
KR20080031001A (ko) * 2005-06-02 2008-04-07 아스트라제네카 아베 Ｃｄ20에 대한 항체 및 그의 용도
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
BRPI0720565A2 (pt) 2006-12-20 2013-09-17 Mmr Information Systems Inc anticorpos e mÉtodos para a sua preparaÇço e seu uso

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003068821A2 (en) * 2002-02-14 2003-08-21 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
WO2004106380A2 (en) * 2003-05-31 2004-12-09 Micromet Ag Human-anti-human cd3 binding molecules
CN1867586A (zh) * 2003-10-16 2006-11-22 麦克罗梅特股份公司 多特异性的去免疫化cd3结合物

Also Published As

Publication number Publication date
US8945550B2 (en) 2015-02-03
CA2832111A1 (en) 2008-07-03
WO2008076487A2 (en) 2008-06-26
JP2010513539A (ja) 2010-04-30
KR101378302B1 (ko) 2014-03-28
US20090285813A1 (en) 2009-11-19
HK1194395A1 (zh) 2014-10-17
KR20090094849A (ko) 2009-09-08
EP2716657A2 (en) 2014-04-09
MX2009006659A (es) 2009-10-12
US20100104553A1 (en) 2010-04-29
CN103709249B (zh) 2016-02-24
KR20130118966A (ko) 2013-10-30
WO2008076487A3 (en) 2008-12-24
KR101546441B1 (ko) 2015-08-24
JP2015145394A (ja) 2015-08-13
EP2121756A4 (en) 2011-08-31
CA2673725A1 (en) 2008-07-03
AU2007338607A1 (en) 2008-07-03
CA2673725C (en) 2016-01-12
EP2716658A2 (en) 2014-04-09
EP2716657A3 (en) 2014-10-08
US8465741B2 (en) 2013-06-18
AU2007338607B2 (en) 2013-03-14
BRPI0720565A2 (pt) 2013-09-17
US20130287766A1 (en) 2013-10-31
EP2716658A3 (en) 2014-10-08
HK1141543A1 (zh) 2010-11-12
JP2014028812A (ja) 2014-02-13
CN103709249A (zh) 2014-04-09
WO2008079466A1 (en) 2008-07-03
CN101675074A (zh) 2010-03-17
EP2121756A1 (en) 2009-11-25

Similar Documents

Publication Publication Date Title
CN101675074B (zh) 抗体及其制备和使用方法
CN103833854B (zh) 免疫球蛋白变体及其用途
TWI381050B (zh) Anti-CD20 monoclonal antibody
JP2022023862A (ja) ヒト化またはキメラｃｄ３抗体
TW202003562A (zh) 抗密連蛋白18.2(cldn18.2)抗體
JP2019519223A (ja) 免疫調節タンパク質及び腫瘍抗原に結合する二重特異性結合タンパク質
CN100460421C (zh) 免疫球蛋白变体及其用途
CN107090034A (zh) M‑csf特异性单克隆抗体及其应用
JP2023520636A (ja) Ｔ細胞二重特異性結合タンパク質
JPWO2007102200A1 (ja) 抗ｃｄ２０モノクローナル抗体
JPWO2009031230A1 (ja) 抗ｃｄ２０モノクローナル抗体
WO2022134645A1 (en) Antibodies binding human and monkey cd3 and uses thereof
KR20240163722A (ko) Ilt3 및 cd3 결합제 및 이의 사용 방법
HK1207870A1 (en) Anti-human sema4a antibodies useful to treat disease
KR20240021959A (ko) 항개 cd20 항체
AU2013202392B2 (en) Antibodies and methods for making and using them
HK1141543B (en) Antibodies and methods for making and using them
HK1194395B (en) Antibodies and methods for making and using them
RU2846103C2 (ru) Антитела к CD20 собачьих

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1141543

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1141543

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160224

Termination date: 20170914

CF01 Termination of patent right due to non-payment of annual fee